Why Shares of Akebia Therapeutics Were Up Tuesday
Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight kidney disease, has seen its shares climb more than 168% so far this year.
On Monday, the company announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing approval for Vafseo (vadadustat) to treat anemia connected with chronic kidney disease in adults on maintenance dialysis. The drug was already approved in April by the European Commission and in Japan in 2020.
That wasn't the only bit of good news for Akebia: The stock's rise has meant that it is no longer in danger of being delisted on the Nasdaq.
Source Fool.com
Akebia Therapeutics Inc. Stock
Our community is currently high on Akebia Therapeutics Inc. with 8 Buy predictions and 3 Sell predictions.
Based on the current price of 1.25 € the target price of 3 € shows a potential of 139.81% for Akebia Therapeutics Inc. which would more than double the current price.
